Functional dyspepsia mechanism
- Duodenal eosinophilia and mast cell activation: FD (particularly postprandial distress syndrome, PDS subtype) is associated with elevated eosinophil counts and activated mast cells in duodenal mucosa. These generate leukotrienes and histamine, sensitising duodenal afferent nerve endings (5-HT3/TRPV1 receptors) to triggering visceral hypersensitivity and impaired fundic relaxation. Spirulina’s GLA→DGLA pathway reduces leukotriene production from eosinophils, potentially reducing the duodenal sensitisation signal.
- Gastric mucosal NOX2: Gastric epithelial cells and mucosal macrophages express NOX2. In FD, H. pylori (present in ~30–50% of FD globally) and dietary antigens activate mucosal NOX2, generating superoxide that activates NF-κB and drives IL-6, TNF-α, and IL-8 production. Phycocyanobilin inhibits mucosal NOX2, reducing this low-grade inflammatory activation.
- Spirulina as a potential trigger: Spirulina polysaccharides can cause mild initial GI symptoms in sensitive individuals (bloating, loose stools) as the microbiome adapts. In FD patients with baseline GI sensitivity: start at 0.5–1 g/day and increase slowly. Take with food rather than on an empty stomach — gastric motility is impaired in FD and fasting spirulina may worsen early satiation.
H. pylori context
- H. pylori infection is present in a significant proportion of FD patients. Eradication therapy (clarithromycin + amoxicillin or metronidazole + PPI, or bismuth quadruple therapy) cures FD symptoms in ~10–15% of H. pylori-positive FD cases (NNT ~15 in trials).
- During H. pylori eradication: No documented pharmacokinetic interaction between spirulina and clarithromycin, amoxicillin, or metronidazole. GI side effects of eradication therapy (nausea, diarrhoea, metallic taste) may overlap with spirulina initiation GI effects. Practical recommendation: do not start spirulina during the 7–14 day eradication course — resume/initiate after completion.
- After eradication: H. pylori eradication restores gastric acid production, improving non-haem iron absorption from spirulina. Post-eradication is an ideal time to start spirulina for nutritional benefit in patients who had FD-associated iron deficiency.
Proton pump inhibitors (PPIs)
- PPIs (omeprazole, lansoprazole, pantoprazole) reduce gastric acid. Reduced acid impairs pepsin-mediated protein digestion and non-haem iron absorption (ferric to ferrous conversion requires acid). In FD patients on long-term PPIs: spirulina non-haem iron absorption is modestly reduced. Pair with vitamin C to partially compensate (ascorbic acid reduces Fe³+ to Fe²+ independently of pH). No pharmacokinetic interaction between spirulina and PPIs.
- Long-term PPI use is also associated with B12 malabsorption. Spirulina pseudocobalamin may produce falsely normal serum B12 in patients on long-term PPIs — use MMA/holoTC for B12 monitoring if on long-term PPI and spirulina simultaneously.
Prokinetics (domperidone, metoclopramide)
- Used for postprandial distress subtype FD. Domperidone and metoclopramide increase gastric motility. No pharmacokinetic interaction with spirulina. Taking spirulina with meals (the recommended approach in FD) aligns with prokinetic timing — take both with the same meal.
Practical guidance
- Always take with food in FD — never on empty stomach; takes advantage of meal-stimulated motility to minimise gastric retention
- Start at 0.5–1 g/day; increase by 0.5 g every 5 days; FD patients have heightened GI sensitivity to any new food
- Do not start during H. pylori eradication course; restart after completion
- Long-term PPI: add vitamin C alongside spirulina to compensate for reduced iron absorption; use MMA/holoTC for B12 monitoring
- If spirulina worsens early satiation or bloating: reduce dose; switch to liquid format (spirulina dissolved in 300 ml of water or kefir) which empties faster than food-mixed spirulina